PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

This study is testing a combination of an immunotherapy drug (PD-1 inhibitor) and a targeted drug called pyrotinib for people with advanced non-small cell lung cancer (NSCLC) that has a specific HER2 insertion mutation and has not responded to first-line chemotherapy. **You may be eligible if...** - You have confirmed advanced non-small cell lung cancer (NSCLC) - Your cancer has a HER2 insertion mutation (a specific change in the HER2 gene) - Your cancer has progressed after first-line standard chemotherapy - You have at least one measurable tumor lesion on imaging **You may NOT be eligible if...** - You have no measurable tumor lesions - You have previously been treated with a PD-1 inhibitor or pyrotinib Talk to your doctor to see if this trial is right for you.